Endothelial cells, fibroblasts and vasculitis

Aims of Therapy/Series Editor: Lorraine Harper

Christopher D. Buckley, G. Ed Rainger1, Gerard B. Nash1 and Karim Raza

Rheumatology Research Group, Division of Immunity and Infection and 1 Division of Medical Sciences, Institute of Biomedical Research, MRC Centre for Immune Regulation, University of Birmingham, Birmingham B15 2TT, UK.

Correspondence to: C. D. Buckley, Department of Rheumatology, Division of Immunity and Infection, University of Birmingham, Birmingham B15 2TT, UK. E-mail: c.d.buckley{at}bham.ac.uk.


    Abstract
 Top
 Abstract
 Introduction
 A key role for...
 The role of dysregulated...
 Systemic vasculitis and global...
 References
 
One of the most important questions in vasculitis research is not why inflammation of blood vessels occurs but why it persists, often in a site-specific manner. In this review we illustrate how stromal cells, such as fibroblasts and pericytes, might play an important role in regulating the site at which vasculitis occurs. Smooth muscle cells and fibroblasts directly influence the behaviour of overlying vascular cells, amplifying the response of the endothelium to proinflammatory agents such as TNF-{alpha} and allowing enhanced and inappropriate leucocyte recruitment. An abnormal local vascular stromal environment can therefore influence local endothelial function and drive the persistence of local vascular inflammation. However, such local vascular inflammation can have distant effects on the systemic vascular system, leading to widespread endothelial cell dysfunction. Vascular endothelial dysfunction is common in a range of immune-mediated inflammatory diseases, is seen in multiple vascular beds, and is reversible following the induction of disease remission. The mechanisms that drive such systemic vascular endothelial dysfunction are unclear but factors such as TNF-{alpha} and CRP may play a role. Persistence of such widespread endothelial dysfunction in systemic vasculitis appears to have long-term consequences, leading to the acceleration of atherosclerosis and premature ischaemic heart disease. It may also underlie the accelerated atherosclerosis seen in other immune-mediated rheumatic diseases, such as rheumatoid arthritis.

KEY WORDS: Vasculitis


    Introduction
 Top
 Abstract
 Introduction
 A key role for...
 The role of dysregulated...
 Systemic vasculitis and global...
 References
 
Cells of the vasculature play a central role in physiology and pathology. Endothelial cells control platelet adhesion, maintain a balance of fibrinolytic and prothrombotic activity, regulate vascular tone and play a critical role in regulating the recruitment of leucocytes into inflammatory sites [1]. Regulation of vascular tone is dependent on the production of vasodilators, such as nitric oxide (NO) and prostacyclin, and vasoconstrictors, such as endothelin. While cells of the vasculature (such as endothelial cells and platelets) have been proposed to be the major producers of vasoconstrictors and vasodilators, it is now becoming clear that stromal cells such as fibroblasts and smooth muscle cells can also produce biologically active proteins that act in a paracrine manner to regulate endothelial cell function [2, 3].

In addition to regulating vascular tone, endothelial cells act as the gatekeepers for tissues, regulating the quality and quantity of leucocytes entering organs during both basal immune surveillance and inflammation [4]. In order to do this they respond to chemokines and other proinflammatory agents that modify the expression of adhesion receptors on the endothelium, leading to the ordered capture and transendothelial migration of leucocytes from flowing blood [5]. However the factors regulating the sites at which transendothelial migration occurs remain unclear [6, 7].

The gene expression profiles and functional properties of endothelial cells vary between vascular beds [8, 9]. For example, the gene expression profiles of arterial, venular and lymphatic endothelial cells are very different, reflecting their different physiological roles, secretory potential and permeability [8]. This variation in function extends to their ability to support transendothelial migration. Whereas endothelial cells in the high endothelial venules of primary and secondary lymphoid organs are particularly adapted to supporting the migration of naive lymphocytes, postcapillary venules in peripheral organs can support more mixed leucocyte traffic, including monocytes and neutrophils [10, 11]. Thus, endothelial cells display considerable diversity in structure and function, both between and within different organs. In this review we examine the consequences of endothelial cell diversity for the site specificity, persistence and priming of different vascular beads to systemic inflammation in vasculitis.


    A key role for the local stromal microenvironment in regulating endothelial function
 Top
 Abstract
 Introduction
 A key role for...
 The role of dysregulated...
 Systemic vasculitis and global...
 References
 
Endothelial cells exist in very close proximity with stromal cells such as pericytes [2]. These interactions help define the physiological properties of specific vascular beds such that the characteristics of endothelial cells in different organs are influenced by the nature of the underlying stromal cells [3, 11]. For example, the glomerular podocytes in the kidney help dictate the filtering function of this high-flow vascular bed. In contrast, the supporting astrocytes in the brain help define and maintain the blood–brain barrier. The molecular mechanisms by which this occurs remain obscure but there is a growing awareness that matrix proteins, which are laid down and matured during development of vascular beds and which help define organ specialization, play a role [11]. Thus the growth characteristics, angiogenic potential and function of endothelial cells in vitro can be directly modified by the type of matrix on which they are grown [12]. Furthermore, recent studies in which endothelial cells are grown in co-culture with different stromal cells, such as smooth muscle cells and fibroblasts, have clearly demonstrated that varying the stromal cells can have dramatic effects on endothelial cell function [13]. Indeed, recent studies examining how stromal fibroblasts support epithelial cell function have shown that cross-talk between stromal cells and their overlying tubular structures is a general feature by which site specificity is defined and maintained [14].


    The role of dysregulated endothelial–stromal interactions in pathology
 Top
 Abstract
 Introduction
 A key role for...
 The role of dysregulated...
 Systemic vasculitis and global...
 References
 
While it remains difficult to unequivocally demonstrate in vivo that changes in the underlying stroma can directly affect endothelial cell function, it is now clear that targeting both stromal cells (pericytes) as well as endothelial cells in the tumour vasculature is required to obtain significant anti-tumour effects [12]. In addition, targeting the paracrine signalling between tumour cells and stromal fibroblasts by disrupting platelet-derived growth factor-receptor {alpha} signalling significantly reduces tumour growth [15]. In vitro models of atherosclerosis have shown that secretory smooth muscle cells can prime co-cultured endothelial cells for TNF-{alpha}-induced leucocyte adhesion via a mechanism that involves TGF-ß [13]. We have recently found that stromal fibroblasts can also modify the behaviour of endothelial cells in co-culture models of chronic synovial inflammation, leading to increased leucocyte recruitment, migration and retention within inflamed tissues. Therefore, an important and evolving concept is that endothelial cell function is pliable and closely regulated both in physiology and pathology by paracrine signals from underlying stromal cells [3, 11]. Moreover, progression to chronic persistent inflammation appears to arise because of changes in stromal fibroblasts, which lead to aberrant leucocyte accumulation within the inflamed tissue [16]. While changes in leucocyte survival, retention and differentiation within inflamed tissue undoubtedly contribute, it is likely that changes in the cross-talk between vascular cells and their underlying stroma also contribute significantly to the location and persistent recruitment of leucocytes into the inflamed tissue.

Thus, in patients with vasculitis, stromal cell/matrix interactions with endothelial cells at the site of inflammation are likely to be important in the initiation and maintenance of the local inflammatory response and the determination of site specificity. In addition, in parallel with these local endothelial changes, and probably secondary to the accompanying systemic inflammatory response, endothelial function is altered at distant sites; an effect which may lead to accelerated atherosclerosis (Fig. 1).



View larger version (15K):
[in this window]
[in a new window]
 
FIG. 1. Vascular endothelium at the site of the primary inflammatory response and at distant sites. Local endothelial activation, regulated by stromal cells and matrix, drives the vasculitic process with leucocyte recruitment, thrombosis and platelet plugging. Such local inflammation has distant effects on the vascular endothelium. This systemic endothelial dysfunction may be a consequence of circulating inflammatory mediators such as TNF-{alpha} and CRP.

 

    Systemic vasculitis and global endothelial cell dysfunction
 Top
 Abstract
 Introduction
 A key role for...
 The role of dysregulated...
 Systemic vasculitis and global...
 References
 
Endothelial function can be measured in vivo by assessing the vasodilatory response to endothelial-dependent stimuli such as increased shear stress or acetylcholine (ACh) infusion, which lead to the release of endothelial NO. Impairment in this vasodilation represents endothelial dysfunction—a central early event in atherosclerosis. Although NO-mediated vasodilatation is the readout used in many in vivo assays of endothelial function, in fact NO is central to the regulation of other endothelial and vascular functions, such as leucocyte adhesion, platelet aggregation and thrombosis, and the growth and migration of vascular smooth muscle cells [17]. Impaired release of NO by vascular endothelium is thus suggestive of a generalized perturbation of endothelial function.

Transient endothelial dysfunction during a transient systemic inflammatory response has been shown after Salmonella typhi vaccination [18]. Similar endothelial dysfunction has been found in the persistent inflammation that characterizes systemic vasculitis. This was first demonstrated in a cross-sectional study which showed impaired flow-mediated vasodilatation at the brachial artery in vasculitis patients [19]. A subsequent larger study confirmed these findings and demonstrated endothelial dysfunction both in patients with ANCA-associated vasculitis (Wegener's granulomatosis and Churg–Strauss syndrome) and in patients with polyarteritis nodosa [20]. The occurrence of endothelial dysfunction at the brachial artery in patients with small-vessel vasculitis, without evidence of brachial artery involvement, suggested that the dysfunction was occurring distant to the site of primary vascular inflammation. An impairment in the cutaneous microvascular vasodilatory response to ACh supported the concept of diffuse endothelial dysfunction in patients with systemic vasculitis [20]. In a separate study, endothelial function, assessed in terms of forearm blood flow response to ACh, was similarly found to be impaired in systemic vasculitis [21]. Data regarding the relationship between disease activity and endothelial function have been conflicting. In the largest cross-sectional study of patients with systemic vasculitis there was no correlation between endothelial function at the brachial artery or cutaneous microvasculature and either the CRP or the clinical Birmingham Vasculitis Activity Score [20]. In a subsequent cross-sectional study of patients with ANCA-associated systemic vasculitis, arterial stiffness (a phenomenon regulated by both structural and functional factors, including endothelium-derived NO) was significantly impaired in patients with vasculitis and correlated with the CRP [21]. Despite conflicting observations in cross-sectional studies, the concept that endothelial function is related to vasculitis disease activity is supported by longitudinal studies showing an improvement in endothelial function following the induction of disease remission. Thus, endothelial function significantly improved following successful treatment with steroid and cyclophosphamide [19] or with infliximab, used either alone or in combination with steroid and cyclophosphamide [22]. This improvement in endothelial function in patients with active disease is important as it suggests that the defect does not represent fixed and irreversible damage.

Although these data suggest that diffuse endothelial dysfunction is a consequence of active inflammation at a distant site, the mechanisms for this remain unclear. Systemic TNF-{alpha} may be an important mediator. TNF-{alpha} impairs endothelium-dependent vasodilatation both in vitro and in human arteries in vivo [23, 24]. Interestingly, whilst the local infusion of TNF-{alpha} into the brachial artery reduced endothelial-dependent vasodilatation, no such effect was seen with IL-6 [24]. A role for TNF-{alpha} is further supported by serial observations in patients with active vasculitis, which have shown a transient improvement in vascular endothelial function following infliximab therapy which deteriorates 10 days after the infusion [25]. Whether TNF-{alpha} is having direct or indirect effects on vascular endothelium is unclear. Several direct effects of TNF-{alpha} have been described. TNF-{alpha} modulates endothelial nitric oxide synthase (eNOS) gene expression at transcriptional and post-transcriptional levels, inhibiting activity of the eNOS gene promoter [26] and destabilizing eNOS mRNA [27]. In addition, TNF-{alpha} stimulates the production of reactive oxygen species in vascular endothelial cells [28]. This can reduce endothelial NO availability through the direct inactivation of NO by superoxide and the oxidative degradation of tetrahydrobiopterin, a critical eNOS cofactor [17]. In addition, the oxidative stress which characterizes inflammatory disease can affect endothelial function through a number of other routes, including the generation of oxidized low-density lipoprotein. The inhibitory effects of TNF-{alpha} on endothelium-dependent vasodilatation are not only mediated by effects on NO production. TNF-{alpha} also inhibits the vasodilatory response to arachidonic acid (the precursor of prostanoid synthesis) [29]. In this study, IL-1 synergized with TNF-{alpha} in impairing endothelium-dependent dilatation but IL-6 had no effect. Though TNF-{alpha} is an attractive candidate, it is likely that the endothelial dysfunction in systemic vasculitis is multifactorial. CRP, for example, has direct effects on arterial endothelium, reducing eNOS expression and bioactivity and reducing prostacyclin release [30–32]. A direct role for CRP in the initiation of vascular injury is supported by the accelerated atherosclerosis seen in apolipoprotein E-deficient mice expressing the human CRP transgene [33]. In addition to these direct effects on the vascular endothelium, cytokines have a range of metabolic effects on adipose tissue, skeletal muscle and the liver, leading to disturbances which include insulin resistance and dyslipidaemia, which themselves affect the vascular endothelium [34, 35].

Diffuse endothelial dysfunction in patients with systemic vasculitis suggests that they are at increased risk of atherosclerosis. Indeed, inflammatory rheumatic diseases in which secondary vasculitis is common, such as rheumatoid arthritis and SLE, are associated with both endothelial dysfunction [36–38] and accelerated cardiovascular disease [39–41]. Historically, the significant morbidity and mortality associated with acute episodes of vasculitis has meant that less attention was paid to long-term consequences of the disease. However, as treatments for acute events improve, the long-term complications, such as accelerated atherosclerosis, become more relevant. To date few groups have addressed this issue and data have only been reported in preliminary form. However, it would appear that in patients with Wegener's granulomatosis the thickness of the carotid artery intima media is increased compared with controls [42] and that the risk of cardiovascular and cerebrovascular disease is increased in patients with ANCA-associated systemic vasculitis [43].

Patients with focal vascular inflammation have perturbations in endothelial function both locally and at distant sites. Local endothelial activation, regulated by stromal cells, drives the vasculitic process with leucocyte recruitment, thrombosis and platelet plugging. Such local vascular inflammation has distant effects on the vascular endothelium. This systemic endothelial dysfunction may be a consequence of circulating inflammatory mediators such as TNF-{alpha} and CRP. In the long term this may lead to accelerated atherosclerosis.


    Acknowledgments
 
Work on endothelial function in the laboratories of G.E.R. and G.B.N. was supported by a Programme Grant (RG/2000011) from the British Heart Foundation. Work in the laboratories of C.D.B and K.R is supported by the MRC and arc. G.E.R. is a British Heart Foundation Senior Non-Clinical Lecturer (BS/97001).

The authors have declared no conflicts of interest.


    References
 Top
 Abstract
 Introduction
 A key role for...
 The role of dysregulated...
 Systemic vasculitis and global...
 References
 

  1. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol 1995;57:827–72.[CrossRef][ISI][Medline]
  2. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res 1996;32:687–98.[CrossRef][ISI][Medline]
  3. Ahmad SA, Jung YD, Liu W et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biology 2002;12:105–12.[CrossRef][ISI]
  4. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003;24:327–34.[ISI][Medline]
  5. Alon R, Feigelson S. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol 2002;14:93–104.[CrossRef][ISI][Medline]
  6. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002;16:1–4.[CrossRef][ISI][Medline]
  7. Yadav R, Larbi KY, Young RE et al. Migration of leukocytes through the vessel wall and beyond. Thromb Haemost 2003;90:598–606.[ISI][Medline]
  8. Chi JT, Chang HY, Haraldsen G et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci USA 2003;100:10623–8.[Abstract/Free Full Text]
  9. Dai G, Kaazempur-Mofrad MR, Natarajan S et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci USA 2004;101:14871–6.[Abstract/Free Full Text]
  10. Choi J, Enis DR, Koh KP et al. T lymphocyte-endothelial cell interactions. Annu Rev Immunol 2004;22:683–709.[CrossRef][ISI][Medline]
  11. Nash GB, Buckley CD, Rainger GE. The local physicochemical environment conditions the proinflammatory response of endothelial cells and thus modulates leukocyte recruitment. FEBS Lett 2004;569:13–7.[CrossRef][ISI][Medline]
  12. Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111:1287–95.[Abstract/Free Full Text]
  13. Rainger GE, Nash GB. Cellular pathology of atherosclerosis: smooth muscle cells prime cocultured endothelial cells for enhanced leukocyte adhesion. Circ Res 2001;88:615–22.[Abstract/Free Full Text]
  14. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332–7.[CrossRef][ISI][Medline]
  15. Dong J, Grunstein J, Tejada M et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004;23:2800–10.[Abstract/Free Full Text]
  16. Buckley CD, Pilling D, Lord JM et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001;22:199–204.[CrossRef][ISI][Medline]
  17. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109:II27–33.[Medline]
  18. Hingorani AD, Cross J, Kharbanda RK et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000;102:994–9.[Abstract/Free Full Text]
  19. Raza K, Thambyrajah J, Townend JN et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000;102:1470–2.[Abstract/Free Full Text]
  20. Filer AD, Gardner-Medwin JM, Thambyrajah J et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis 2003;62:162–7.[Abstract/Free Full Text]
  21. Booth AD, Wallace S, McEniery CM et al. Inflammation and arterial stiffness in systemic vasculitis: A model of vascular inflammation. Arthritis Rheum 2004;50:581–8.[CrossRef][ISI][Medline]
  22. Booth AD, Jayne DR, Kharbanda RK et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004;109:1718–23.[Abstract/Free Full Text]
  23. Wimalasundera R, Fexby S, Regan L et al. Effect of tumour necrosis factor-alpha and interleukin 1beta on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro. Br J Pharmacol 2003;138:1285–94.[CrossRef][ISI][Medline]
  24. Chia S, Qadan M, Newton R et al. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 2003;23:695–701.[Abstract/Free Full Text]
  25. Stevens RJ, Gardner-Medwin JM, Carruthers DM et al. Endothelial dysfunction improves acutely after infliximab. Rheumatology 2002;41:24.
  26. Anderson HD, Rahmutula D, Gardner DG. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem 2004;279:963–9.[Abstract/Free Full Text]
  27. Lai PF, Mohamed F, Monge JC et al. Downregulation of eNOS mRNA expression by TNFalpha: identification and functional characterization of RNA–protein interactions in the 3'UTR. Cardiovasc Res 2003;59:160–8.[CrossRef][ISI][Medline]
  28. Corda S, Laplace C, Vicaut E et al. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol 2001;24:762–8.[Abstract/Free Full Text]
  29. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997;96:3042–7.[Abstract/Free Full Text]
  30. Venugopal SK, Devaraj S, Yuhanna I et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002;106:1439–41.[Abstract/Free Full Text]
  31. Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913–9.[Abstract/Free Full Text]
  32. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003;108:1676–8.[Abstract/Free Full Text]
  33. Paul A, Ko KW, Li L et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109:647–55.[Abstract/Free Full Text]
  34. Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. Am J Med 2004;117:109–17.[CrossRef][ISI][Medline]
  35. Sattar N, McCarey DW, Capell H et al. Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957–63.[Abstract/Free Full Text]
  36. Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184–7.[Abstract/Free Full Text]
  37. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003;114:647–52.[CrossRef][ISI][Medline]
  38. El Magadmi M, Bodill H, Ahmad Y et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004;110:399–404.[Abstract/Free Full Text]
  39. Banks M, Flint J, Bacon PA, Kitas GD. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease. Arthritis Rheum 2000;43:385.
  40. del Rincon ID, Williams K, Stern MP et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.[CrossRef][ISI][Medline]
  41. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408–15.[Abstract]
  42. Zaenker M, Aries PM, Herlyn K et al. Accelerated atherosclerosis in Wegener's granulomatosis (WG): a sonographic case-control study on intima media thickness. Arthritis Rheum 2002;46:S185.
  43. Salisbury EM, McLaren JS, Jayne DRW et al. Cardiovascular and cerebrovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis. Rheumatology 2004;43:ii9.
Submitted 1 December 2004; revised version accepted 10 December 2004.



This Article
Abstract
Full Text (PDF)
All Versions of this Article:
44/7/860    most recent
keh542v1
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Search for citing articles in:
ISI Web of Science (1)
Disclaimer
Request Permissions
Google Scholar
Articles by Buckley, C. D.
Articles by Raza, K.
PubMed
PubMed Citation
Articles by Buckley, C. D.
Articles by Raza, K.
Related Collections
Other Rheumatology